Combining hyperthermia with standard of care of the treatment for Astrocytoma improves the 3 month treatment response by 480% and significantly increased the amount of patients alive at 5 years by 3.4 x; i.e. from 25% 5yr survival of to an 83% 5yr survival.

Similarly, when using modulated electrohyperthermia to treat Glioblastomas in combination with standard of care of the treatment; the scan results and overall treatment response in 3 months improved by 725% comparatively but with only a modest impact on overall 5 year survival for patients given that little to no further treatments were provided over and above initial basic standard of care. Glioblastoma remains a very challenging condition to treat long term, however several new clinical trials are underway with promising results for improving outcomes and quality of life in patients with GBM.

TMZ sensitivity: A further small Glioblastoma study from Germany revealed that hyperthermia significantly enhanced the efficacy of 21/28 day Temozolomide regime and with an appreciable increase in quality adjusted life years and related cost savings.

Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicentre Controlled Study 

There are interesting studies on glioma therapy with modulated electrohyperthermia (mEHT), which combines heat therapy with an electric field. Clinical researchers not only found the mEHT method feasible for palliation but also reported evidence of therapeutic response.

Tumor response at the 3-month follow-up was observed in 29% and 48% of GBM and AST patients after mEHT, and in 4% and 10% of GBM and AST patients after BSC, respectively.

The survival rate at first and second year in the mEHT group was 77.3% and 40.9% for AST, and 61% and 29% for GBM, respectively.

The 5-year overall survival of AST was 83% after mEHT versus 25% after BSC and 3.5% after mEHT versus 1.2% after BSC for GBM.”

Tumor response at the 3-month follow-up was observed in 29% and 48% of GBM and AST patients after mEHT, and in 4% and 10% of GBM and AST patients after BSC, respectively.

Combining loco regional electrohyperthermia with the basic standard of care treatment improves the 5 year overall survival by 58% in patients with Astrocytoma Vs basic standard of care without hyperthermia.